Contracts › 75F40125C00095
75F40125C00095: Baa# FY25C3AP3 - (H20) a Next Generation Medical Countermeasures Scientific Platform for Regulatory Evaluation and Preparedness
Awarded to Dna Hive Llc by Food and Drug Administration (FDA).
$3.1Mobligated
$3.1Mpotential value
29 September 2028current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75F40125C00095 |
|---|---|
| Awardee | Dna Hive Llc |
| Awarding agency | Food and Drug Administration (FDA) |
| Awarding office | FDA OFFICE OF ACQ GRANT SVCS |
| NAICS | 541714 Research and Development in Biotechnology (Except Nanobiotechnology) |
| PSC | AN11 Health R&D Services; Health Care Services; Basic Research |
| Place of performance | MD |
| Offers received | 1 |
| Period of performance | 23 September 2025 to 29 September 2028 |
| Potential end | 29 September 2028 |
| Estimated recompete solicitation | ~Q2 2028 (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 04 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541714 contracts · All expiring contracts · USASpending record